MX2019005742A - Inhibidores de antigeno de membrana especifico de la prostata (psma) de union a albumina. - Google Patents

Inhibidores de antigeno de membrana especifico de la prostata (psma) de union a albumina.

Info

Publication number
MX2019005742A
MX2019005742A MX2019005742A MX2019005742A MX2019005742A MX 2019005742 A MX2019005742 A MX 2019005742A MX 2019005742 A MX2019005742 A MX 2019005742A MX 2019005742 A MX2019005742 A MX 2019005742A MX 2019005742 A MX2019005742 A MX 2019005742A
Authority
MX
Mexico
Prior art keywords
formula
albumin
compound
pharmaceutically acceptable
binding psma
Prior art date
Application number
MX2019005742A
Other languages
English (en)
Spanish (es)
Inventor
Berkman Clifford
Choy Cindy
Original Assignee
Cancer Targeted Tech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Targeted Tech Llc filed Critical Cancer Targeted Tech Llc
Publication of MX2019005742A publication Critical patent/MX2019005742A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/081—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the protein being an albumin, e.g. human serum albumin [HSA], bovine serum albumin [BSA], ovalbumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/08—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with two six-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2019005742A 2016-11-23 2017-11-24 Inhibidores de antigeno de membrana especifico de la prostata (psma) de union a albumina. MX2019005742A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662425810P 2016-11-23 2016-11-23
PCT/US2017/063182 WO2018098390A1 (en) 2016-11-23 2017-11-24 Albumin-binding psma inhibitors

Publications (1)

Publication Number Publication Date
MX2019005742A true MX2019005742A (es) 2019-09-13

Family

ID=60812130

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005742A MX2019005742A (es) 2016-11-23 2017-11-24 Inhibidores de antigeno de membrana especifico de la prostata (psma) de union a albumina.

Country Status (8)

Country Link
US (1) US11147889B2 (cg-RX-API-DMAC7.html)
EP (1) EP3544960A1 (cg-RX-API-DMAC7.html)
JP (1) JP7167021B2 (cg-RX-API-DMAC7.html)
CN (1) CN109982998A (cg-RX-API-DMAC7.html)
BR (1) BR112019010206A2 (cg-RX-API-DMAC7.html)
CA (1) CA3043619A1 (cg-RX-API-DMAC7.html)
MX (1) MX2019005742A (cg-RX-API-DMAC7.html)
WO (1) WO2018098390A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102884167B1 (ko) * 2017-10-22 2025-11-12 프로빈셜 헬스 서비시즈 오쏘리티 전립선 특이적 막 항원-발현 암의 진단 또는 치료를 위한 신규한 라디오메탈-결합 화합물
WO2019246445A1 (en) * 2018-06-20 2019-12-26 The Research Foundation For The State University Of New York Triazamacrocycle-derived chelator compositions for coordination of imaging and therapy metal ions and methods of using same
EP3880253A1 (en) * 2018-11-14 2021-09-22 Noria Therapeutics, Inc. Thioamide-containing compositions and methods of use thereof
WO2020108753A1 (en) * 2018-11-28 2020-06-04 ITM Isotopen Technologien München AG Novel tumor antigen binding agents and uses thereof
US12472272B2 (en) 2019-04-17 2025-11-18 Provincial Health Services Authority Radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen- expressing cancer
CN119431260A (zh) 2019-06-21 2025-02-14 省卫生服务机构 靶向前列腺特异性膜抗原的放射性标记化合物
EP4116306A4 (en) 2020-03-04 2024-05-29 Nihon Medi-Physics Co., Ltd Compound and radioactive labeling compound
WO2021225760A1 (en) * 2020-05-06 2021-11-11 Cornell University Copper-containing theragnostic compounds and methods of use
US20240131206A1 (en) * 2020-12-04 2024-04-25 The Regents Of The University Of California Peptide receptor radionuclide therapy
EP4263509A4 (en) * 2020-12-16 2024-12-04 The University of British Columbia RADIOACTIVELY LABELLED COMPOUNDS FOR TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN
CN114685599A (zh) * 2020-12-30 2022-07-01 南京江原安迪科正电子研究发展有限公司 一种psma靶向抑制剂及放射性核素标记的psma靶向抑制剂、制备方法和用途
KR20230154183A (ko) 2021-03-04 2023-11-07 니혼 메디피직스 가부시키가이샤 화합물 및 방사성 표지 화합물
US20250186627A1 (en) * 2022-03-04 2025-06-12 Provincial Health Services Authority Radiolabeled compounds targeting the prostate-specific membrane antigen
WO2024126687A1 (en) * 2022-12-16 2024-06-20 Silence Therapeutics Gmbh Nucleic acids conjugated to an albumin binding moiety
EP4667019A1 (en) * 2023-02-16 2025-12-24 Norroy Bioscience Co., Ltd. Psma-targeted radiopharmaceutical, and synthesis and use thereof
CN116217505B (zh) * 2023-03-17 2024-10-01 南京医科大学 用于诊断或治疗表达前列腺特异性膜抗原癌症的新型标记靶向剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0621973D0 (en) * 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
CA3035532C (en) * 2009-03-19 2021-10-26 The Johns Hopkins University Psma-targeting compounds and uses thereof
HUE045028T2 (hu) * 2011-08-05 2019-12-30 Molecular Insight Pharm Inc Radiojelzett prosztataspecifikus membrán antigén inhibitorok
WO2013028664A1 (en) * 2011-08-22 2013-02-28 Siemens Medical Solutions Usa, Inc. Psma imaging agents
CA2929651A1 (en) * 2013-11-06 2015-05-14 Solstice Biologics, Ltd. Polynucleotide constructs having disulfide groups
US20160287731A1 (en) * 2013-11-14 2016-10-06 Endocyte, Inc. Compounds for Positron Emission Tomography
EP3183236B1 (en) * 2014-08-24 2022-04-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften Method for the production of 18f-labeled active esters and their application exemplified by the preparation of a psma-specific pet-tracer
AU2016333334B2 (en) * 2015-09-30 2019-07-25 Deutsches Krebsforschungszentrum 18F-tagged inhibitors of prostate specific membrane antigen (PSMA) and their use as imaging agents for prostate cancer
WO2017165473A1 (en) * 2016-03-22 2017-09-28 The Johns Hopkins University Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
JP7317505B2 (ja) * 2016-06-23 2023-07-31 コーネル ユニバーシティー 腫瘍死滅に影響する二重標的構築物
DE102016122273B4 (de) * 2016-11-18 2018-06-21 Abx Advanced Biochemical Compounds Gmbh Präkursoren für die Radiofluorierung

Also Published As

Publication number Publication date
US11147889B2 (en) 2021-10-19
WO2018098390A1 (en) 2018-05-31
US20200061218A1 (en) 2020-02-27
JP2019535754A (ja) 2019-12-12
CA3043619A1 (en) 2018-05-31
CN109982998A (zh) 2019-07-05
EP3544960A1 (en) 2019-10-02
BR112019010206A2 (pt) 2019-09-03
JP7167021B2 (ja) 2022-11-08

Similar Documents

Publication Publication Date Title
MX2019005742A (es) Inhibidores de antigeno de membrana especifico de la prostata (psma) de union a albumina.
CY1125021T1 (el) Κιναζολινες ως αναστολεις διαυλων ιοντων καλιου
PH12022551574A1 (en) Egfr inhibitors
MX2018008168A (es) Inhibidores de antigenos de membrana especificos de la prostata (psma) basados en la urea para imaginologia y terapia.
MX2023004309A (es) Inhibidores de quinasa alk2 que contienen imidazol.
PH12018502227A1 (en) Macrocyclic mcl1 inhibitors for treating cancer
MX352672B (es) Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
WO2011116299A3 (en) Myeloid derived suppressor cell inhibiting agents
BR112012029994A2 (pt) composto heterocíclicos como inibidores de janus quinase
PH12015500360A1 (en) Pyrazolopyrimidine compound
PH12021552482A1 (en) Compounds targeting prmt5
EP3777898A3 (en) Compounds for positron emission tomography
GEP20237479B (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EA201270247A1 (ru) Способы применения с-мет-модуляторов
EA201491362A1 (ru) Анестезирующие соединения и способы их применения
EA201692542A1 (ru) Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы
EA201170617A1 (ru) Пиразолиламинопиридины в качестве ингибиторов fak
AU2017216846A8 (en) Pyrrolobenzodiazepine conjugates
MX2021006544A (es) Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
MX2012013206A (es) Inhibidores de quinasa biciclica fusionada.
MX2012001420A (es) Derivados de pirrolo[1,2-b]piridazina como inhibidores de cinasa janus.
NI200900183A (es) Compuestos de pirido [2,3-d] pirimidina - 7 - ona como inhibidores de pi3k - alfa para el tratamiento del cáncer.
MX2016002795A (es) Compuestos de triazolona y usos de los mismos.
BR112019002560A2 (pt) composto, composição farmacêutica, uso de um composto, e, método